Outsourcing a vaccine means buying across several platforms (mRNA/LNP, viral vector, protein subunit, conjugate, live-attenuated), since the immune response is the product. Buyers source CRO and CDMO work for antigen design, immunogenicity and potency assays, adjuvant formulation, GMP drug substance and fill-finish, and assay validation. On BioBridgeX, a neutral marketplace, buyers compare qualified suppliers and contract directly with their chosen supplier, free to the buyer.
Vaccine CRO and CDMO vendors (68)
TRiCBIO
VCHP Clinical Solutions
Nipro PharmaPackaging
CDMO · Drug Product Manufacturing, Aseptic Fill-Finish, QC & Release Testing
Emergent BioSolutions (CDMO Services)
CDMO · Process Development, Drug Substance: Biologics, Drug Product Manufacturing
Symbiosis Pharmaceutical Services
CDMO · Aseptic Fill-Finish, Drug Product Manufacturing, QC & Release Testing
Kindeva Drug Delivery
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Grand River Aseptic Manufacturing (GRAM)
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Jubilant HollisterStier
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Fresenius Kabi Contract Manufacturing
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Simtra BioPharma Solutions
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Vetter Pharma
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Recipharm
CDMO · mRNA / RNA Manufacturing, LNP / Delivery Formulation, Drug Product Manufacturing
Acuitas Therapeutics
CDMO · LNP / Delivery Formulation, Formulation Development, Process Development
Fujifilm (Toyama Chemical / FUJIFILM Diosynth LNP)
CDMO · mRNA / RNA Manufacturing, LNP / Delivery Formulation, Aseptic Fill-Finish
Northern RNA
CDMO · mRNA / RNA Manufacturing, LNP / Delivery Formulation, Plasmid DNA Manufacturing
TriLink BioTechnologies (Maravai LifeSciences)
CDMO · mRNA / RNA Manufacturing, Peptide / Oligo Synthesis, Process Development
Polymun Scientific
CDMO · LNP / Delivery Formulation, mRNA / RNA Manufacturing, Formulation Development
Advanced BioScience Laboratories (ABL)
CDMO · Viral Vector Manufacturing, Process Development, Analytical Development
Vernal Biosciences
CDMO · mRNA / RNA Manufacturing, LNP / Delivery Formulation, Plasmid DNA Manufacturing
IDT Biologika
CDMO · Viral Vector Manufacturing, Process Development, Analytical Development
Vibalogics (ReciBioPharm / Recipharm)
CDMO · Viral Vector Manufacturing, Process Development, Analytical Development
Esco Aster
CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Cell Therapy Manufacturing
National Resilience
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, mRNA / RNA Manufacturing
FUJIFILM Biotechnologies (formerly FUJIFILM Diosynth)
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Process Development
Oxford Biomedica
CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Process Development
Catalent
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Plasmid DNA Manufacturing
Wacker Biotech
CDMO · Process Development, Analytical Development, Drug Substance: Biologics
Richter BioLogics (Richter-Helm)
CDMO · Process Development, Analytical Development, Drug Substance: Biologics
Cytovance Biologics
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
GBI (Goodwin Biotechnology)
CDMO · Process Development, Analytical Development, Drug Substance: Biologics
ProBioGen
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
KBI Biopharma
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
FUJIFILM Diosynth Biotechnologies
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
WuXi Biologics
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Pfizer CentreOne
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Thermo Fisher Scientific (Patheon)
CRO & CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Fareva
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Eurofins (Pharma Discovery & Bioanalytical Services)
CRO & CDMO · Bioanalytical Services, Central Laboratory Services, Genetic Toxicology
Synexa Life Sciences
CRO · Biomarker Discovery & Development, Bioanalytical Services, Immunogenicity & Immunotoxicology
CellCarta
CRO · Biomarker Discovery & Development, Bioanalytical Services, Immunogenicity & Immunotoxicology
Certara
CRO · PK/PD & Modeling, Biostatistics & Statistical Programming, Medical Writing
ACM Global Laboratories
CRO · Central Laboratory Services, Biomarker Discovery & Development, Bioanalytical Services
LabConnect
CRO · Central Laboratory Services, Biomarker Discovery & Development, Clinical Data Management
Labcorp
CRO & CDMO · Central Laboratory Services, GLP Toxicology, Safety Pharmacology
Q2 Solutions
CRO · Central Laboratory Services, Biomarker Discovery & Development, Bioanalytical Services
BioAgilytix Labs
CRO · Bioanalytical Services, Immunogenicity & Immunotoxicology, Biomarker Discovery & Development
Noble Life Sciences
CRO · In Vitro Pharmacology, GLP Toxicology, Bioanalytical Services
JOINN Laboratories / Biomere
CRO · GLP Toxicology, Safety Pharmacology, Toxicokinetics (TK)
KCAS Bio
CRO · Bioanalytical Services, Biomarker Discovery & Development, Immunogenicity & Immunotoxicology
Lovelace Biomedical
CRO · GLP Toxicology, Safety Pharmacology, Toxicokinetics (TK)
IIT Research Institute (IITRI)
CRO · GLP Toxicology, Safety Pharmacology, Toxicokinetics (TK)
BioAgilytix
CRO · Bioanalytical Services, Immunogenicity & Immunotoxicology, Biomarker Discovery & Development
Scantox
CRO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
Labcorp (Labcorp Drug Development / former Covance)
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
Charles River Laboratories
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
Cromos Pharma
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Cytel
CRO · Biostatistics & Statistical Programming, Clinical Data Management, Clinical Operations
Tigermed
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
ClinChoice
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Emmes
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Veristat
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Syneos Health
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Fortrea
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
PPD (Thermo Fisher Scientific)
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Parexel
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
ICON plc
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
IQVIA
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
What does it take to develop and manufacture a Vaccine drug?
A vaccine is unusual among modalities because the thing you are selling is an immune response, not a molecule that acts directly on a target. That one fact reshapes the whole development program. Your readout is not a binding constant or a tumor-growth curve, it is whether the construct raises the right kind of immunity (neutralizing antibodies, a balanced T-cell response, durability over time) and whether it does so without unacceptable reactogenicity. So discovery here is antigen design and selection: choosing the immunogen (a surface protein, a stabilized prefusion conformation, a polysaccharide, an attenuated organism, or an mRNA-encoded antigen), then proving it in immunogenicity and challenge studies in animal models before anything goes near a person.
The other complication is that vaccine is not one platform, it is at least five, and the CRO and CDMO work splits hard along those lines. An mRNA vaccine is an in-vitro-transcription program with LNP encapsulation, so it pulls in RNA drug substance, lipid formulation, and fill-finish. A viral-vector vaccine (adenoviral, for example) is a cell-culture and downstream-purification problem closer to gene therapy. A protein-subunit vaccine is recombinant-protein expression plus, almost always, an adjuvant. A conjugate vaccine chemically links a polysaccharide to a carrier protein. A live-attenuated or inactivated vaccine is classic biologics fermentation or egg or cell-based culture. The capabilities that matter, and the suppliers who have them, are different in each case.
This is exactly where a specialist vaccine CDMO pulls away from a generalist. The wet-lab steps (express a protein, run a bioreactor, fill a vial) look generic on a capability slide, but vaccines carry their own baggage: adjuvant formulation and characterization (aluminum salts, oil-in-water emulsions like squalene-based systems, TLR-agonist adjuvants), a potency assay that actually predicts protection rather than just measuring how much antigen is present, immunogenicity assays validated to read the response (ELISA, neutralization titers, ELISpot, intracellular cytokine staining by flow), and cold-chain or lyophilization to keep a fragile biologic stable. A generalist CDMO can make the drug substance; a vaccine-experienced one knows how to prove it works and how to keep it alive in a vial. Match the supplier to your platform before anything else, because a brilliant mRNA shop is irrelevant to a conjugate program, and vice versa.
How do you choose a CRO or CDMO for Vaccine?
Vaccine is a platform-first decision, more so than most modalities, because the safety, analytical, and manufacturing baggage changes completely between mRNA, viral vector, protein subunit, conjugate, and live-attenuated. Score two or three suppliers against the same written scope (platform, antigen, scale, quality grade, whether adjuvant and fill-finish are included) so you are comparing the same work and not three differently shaped quotes. The checklist below is what actually predicts a usable program.
- Relevant platform and track record: real, completed work in your specific platform (mRNA/LNP, adenoviral or other viral vector, recombinant protein subunit, polysaccharide conjugate, live-attenuated or inactivated), not a generic vaccine claim. Ask for comparable programs the team has taken from construct to clinical material, and which antigens or vectors they have actually handled.
- GxP and analytical capability for vaccines: GMP status (21 CFR Part 211, EU GMP) for clinical supply and GLP for the safety package, plus the vaccine-specific analytics that decide the program. That means a validated potency assay tied to the mechanism of protection, immunogenicity readouts (neutralizing-antibody titers, ELISA, ELISpot, intracellular cytokine staining), and identity, purity, and stability methods, qualified or validated rather than improvised per batch.
- Adjuvant and formulation experience: if your subunit or inactivated program needs an adjuvant, confirm the supplier can formulate and characterize it (aluminum salts, oil-in-water emulsion, liposomal or TLR-agonist systems) and has done so before. For mRNA, confirm LNP encapsulation scope; for lyophilized or cold-chain products, confirm the lyo cycle development and stability program.
- Capacity and scale: the slot availability and the scale you can grow into, from milligram or small-batch tox material through clinical supply and, if relevant, the very large volumes vaccines often need at commercial. A site built for a few liters is the wrong choice for a population-scale program, and an industrial vaccine plant is over-built for a small therapeutic-vaccine trial. Ask where the critical path sits (often template, seed-bank, raw-material lead times, or assay readiness rather than the core reaction).
- Regulatory experience: which agencies the supplier has filed and been inspected by (FDA CBER, EMA, WHO prequalification for global-health programs), and whether they understand the vaccine-specific expectations, including the comparability and lot-consistency work regulators look for. A clean inspection history in your target market is worth more than a low per-unit price.
- IP and confidentiality: who owns process improvements and any platform-derived inventions, how your antigen sequence, vector, or strain is protected, freedom-to-operate on licensed adjuvant or delivery technology (LNP lipids and certain adjuvants are heavily patented), and clean tech-transfer terms if you move the process to another site later.
Frequently asked questions
What CRO and CDMO services does a vaccine program actually need?
Why does the vaccine platform change which CDMO I should use?
What is a potency assay for a vaccine and why is it hard?
Do I need an adjuvant, and can a CDMO formulate it?
What immunogenicity assays should a vaccine CRO run?
Can BioBridgeX coordinate a multi-platform vaccine program across several suppliers?
Source Vaccine work with one contract
Compare transparent quotes from qualified Vaccine CRO and CDMO vendors, then contract once. Free for buyers.
Compare quotes